Independent validation of the PrecivityAD2™ blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment
8.4
来源：
Nature
关键字：
ML brain science
发布时间：
2025-09-04 19:32
摘要：
The independent validation of the PrecivityAD2 blood test confirms its high diagnostic accuracy for identifying brain amyloid pathology in individuals with cognitive impairment. The study reports an AUC-ROC of 0.95 and an overall accuracy of 91%, demonstrating the test's reliability and robustness in clinical settings. This blood biomarker test offers a non-invasive alternative to traditional diagnostic methods, potentially improving early diagnosis and treatment of Alzheimer's disease.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.8
关键证据
The APS2 diagnostic performance was determined using amyloid PET as the reference standard with high concordance (AUC–ROC 0.95).
The study demonstrated an overall accuracy of 91% for the APS2 test in identifying brain amyloid pathology.
The findings support the test's use as an alternative to CSF or amyloid PET assessments.
真实性检查
否
AI评分总结
The independent validation of the PrecivityAD2 blood test confirms its high diagnostic accuracy for identifying brain amyloid pathology in individuals with cognitive impairment. The study reports an AUC-ROC of 0.95 and an overall accuracy of 91%, demonstrating the test's reliability and robustness in clinical settings. This blood biomarker test offers a non-invasive alternative to traditional diagnostic methods, potentially improving early diagnosis and treatment of Alzheimer's disease.